Correspondence 0001193125-24-127432 from Prelude Therapeutics Inc (PRLD) (CIK 0001678660) (PRLD)
Prelude Therapeutics Inc (PRLD) (CIK 0001678660)
Date: May 1, 2024 · CIK: 0001678660 · Accession: 0001193125-24-127432
AI Filing Summary & Sentiment
File numbers found in text: 333-277123
Letter
PRELUDE THERAPEUTICS INCORPORATED
175 Innovation Boulevard
Wilmington, Delaware 19805
May 1, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Alan Campbell
Re: Prelude Therapeutics Incorporated, Registration Statement on Form S-3 (File No. 333-277123) filed February 16, 2024.
Requested Date: May 3, 2024
Requested Time: 4:30 PM Eastern Time
Ladies and Gentlemen:
Prelude Therapeutics Incorporated (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission.
The Registrant hereby authorizes Robert Freedman or Julia Forbess, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to Mr. Freedman at (206) 389-4524 or, in his absence, to Ms. Forbess at (415) 875-2420.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
Sincerely,
Prelude Therapeutics Incorporated
Show Raw Text
CORRESP 1 filename1.htm CORRESP PRELUDE THERAPEUTICS INCORPORATED 175 Innovation Boulevard Wilmington, Delaware 19805 May 1, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Alan Campbell Re: Prelude Therapeutics Incorporated, Registration Statement on Form S-3 (File No. 333-277123) filed February 16, 2024. Requested Date: May 3, 2024 Requested Time: 4:30 PM Eastern Time Ladies and Gentlemen: Prelude Therapeutics Incorporated (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes Robert Freedman or Julia Forbess, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration. The Registrant requests that it be notified of such effectiveness by a telephone call to Mr. Freedman at (206) 389-4524 or, in his absence, to Ms. Forbess at (415) 875-2420. [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] Sincerely, Prelude Therapeutics Incorporated By: /s/ Bryant Lim Bryant Lim Chief Legal Officer, Corporate Secretary, and Interim Chief Financial Officer cc: Kris Vaddi, Chief Executive Officer Prelude Therapeutics Incorporated Robert Freedman, Esq. Julia Forbess, Esq. Fenwick & West LLP